Skip to main content

Articles

Page 1 of 23

  1. More than 40 pathogenic heterozygous PRNP mutations causing inherited prion diseases have been identified to date. Recessive inherited prion disease has not been described to date.

    Authors: Teresa Ximelis, Alba Marín-Moreno, Juan Carlos Espinosa, Hasier Eraña, Jorge M. Charco, Isabel Hernández, Carmen Riveira, Daniel Alcolea, Eva González-Roca, Iban Aldecoa, Laura Molina-Porcel, Piero Parchi, Marcello Rossi, Joaquín Castilla, Raquel Ruiz-García, Ellen Gelpi…

    Citation: Alzheimer's Research & Therapy 2021 13:176

    Content type: Research

    Published on:

  2. To better understand the etiology and pathomechanisms of Alzheimer’s disease, several transgenic animal models that overexpress human tau or human amyloid-beta (Aβ) have been developed. In the present study, w...

    Authors: Thomas Filip, Severin Mairinger, Joerg Neddens, Michael Sauberer, Stefanie Flunkert, Johann Stanek, Thomas Wanek, Nobuyuki Okamura, Oliver Langer, Birgit Hutter-Paier and Claudia Kuntner

    Citation: Alzheimer's Research & Therapy 2021 13:175

    Content type: Research

    Published on:

  3. We recently reported that CSF phosphorylated tau (p-Tau181) relative to Aβ40 (CSF p-Tau/Aβ40 ratio) was less noisy and increased associations with Alzheimer’s disease (AD) biomarkers compared to CSF p-Tau181 alon...

    Authors: Tengfei Guo, Susan M. Landau and William J. Jagust

    Citation: Alzheimer's Research & Therapy 2021 13:174

    Content type: Research

    Published on:

  4. Brain Health Services are a novel approach to the personalized prevention of dementia. In this paper, we consider how such services can best reflect their social, cultural, and economic context and, in doing s...

    Authors: Richard Milne, Daniele Altomare, Federica Ribaldi, José Luis Molinuevo, Giovanni B. Frisoni and Carol Brayne

    Citation: Alzheimer's Research & Therapy 2021 13:173

    Content type: Review

    Published on:

  5. Cognitive complaints in the absence of objective cognitive impairment, observed in patients with subjective cognitive decline (SCD), are common in old age. The first step to postpone cognitive decline is to us...

    Authors: Andrea Brioschi Guevara, Melanie Bieler, Daniele Altomare, Marcelo Berthier, Chantal Csajka, Sophie Dautricourt, Jean-François Démonet, Alessandra Dodich, Giovanni B. Frisoni, Carlo Miniussi, José Luis Molinuevo, Federica Ribaldi, Philip Scheltens and Gael Chételat

    Citation: Alzheimer's Research & Therapy 2021 13:172

    Content type: Review

    Published on:

  6. Although prevention of dementia and late-life cognitive decline is a major public health priority, there are currently no generally established prevention strategies or operational models for implementing such...

    Authors: Alina Solomon, Ruth Stephen, Daniele Altomare, Emmanuel Carrera, Giovanni B. Frisoni, Jenni Kulmala, José Luis Molinuevo, Peter Nilsson, Tiia Ngandu, Federica Ribaldi, Bruno Vellas, Philip Scheltens and Miia Kivipelto

    Citation: Alzheimer's Research & Therapy 2021 13:171

    Content type: Review

    Published on:

  7. Growing evidence suggests dementia incidence can be reduced through prevention programs targeting risk factors. To accelerate the implementation of such prevention programs, a new generation of brain health se...

    Authors: Leonie N. C. Visser, Carolina Minguillon, Gonzalo Sánchez-Benavides, Marc Abramowicz, Daniele Altomare, Karine Fauria, Giovanni B. Frisoni, Jean Georges, Federica Ribaldi, Philip Scheltens, Jetske van der Schaar, Marissa Zwan, Wiesje M. van der Flier and José Luis Molinuevo

    Citation: Alzheimer's Research & Therapy 2021 13:170

    Content type: Review

    Published on:

  8. We envisage the development of new Brain Health Services to achieve primary and secondary dementia prevention. These services will complement existing memory clinics by targeting cognitively unimpaired individ...

    Authors: Janice M. Ranson, Timothy Rittman, Shabina Hayat, Carol Brayne, Frank Jessen, Kaj Blennow, Cornelia van Duijn, Frederik Barkhof, Eugene Tang, Catherine J. Mummery, Blossom C. M. Stephan, Daniele Altomare, Giovanni B. Frisoni, Federica Ribaldi, José Luis Molinuevo, Philip Scheltens…

    Citation: Alzheimer's Research & Therapy 2021 13:169

    Content type: Review

    Published on:

  9. Dementia has a devastating impact on the quality of life of patients and families and comes with a huge cost to society. Dementia prevention is considered a public health priority by the World Health Organizat...

    Authors: Daniele Altomare, José Luis Molinuevo, Craig Ritchie, Federica Ribaldi, Emmanuel Carrera, Bruno Dubois, Frank Jessen, Laura McWhirter, Philip Scheltens, Wiesje M. van der Flier, Bruno Vellas, Jean-François Démonet and Giovanni B. Frisoni

    Citation: Alzheimer's Research & Therapy 2021 13:168

    Content type: Review

    Published on:

  10. Given that tau accumulation, not amyloid-β (Aβ) burden, is more closely connected with cognitive impairment in Alzheimer’s disease (AD), a detailed understanding of the tau-related characteristics of cognitive...

    Authors: Eun Hyun Seo, Ho Jae Lim, Hyung-Jun Yoon, Kyu Yeong Choi, Jang Jae Lee, Jun Young Park, Seong Hye Choi, Hoowon Kim, Byeong C. Kim and Kun Ho Lee

    Citation: Alzheimer's Research & Therapy 2021 13:167

    Content type: Research

    Published on:

  11. This study aimed to clarify the neuropsychiatric symptoms of right-sided predominant semantic dementia (SD-R) by comparing them with those of behavioral variant frontotemporal dementia (bvFTD), left-sided pred...

    Authors: Shunsuke Sato, Mamoru Hashimoto, Kenji Yoshiyama, Hideki Kanemoto, Maki Hotta, Shingo Azuma, Takashi Suehiro, Kyosuke Kakeda, Yoshitaka Nakatani, Sumiyo Umeda, Ryuji Fukuhara, Minoru Takebayashi and Manabu Ikeda

    Citation: Alzheimer's Research & Therapy 2021 13:166

    Content type: Research

    Published on:

  12. Accumulation of amyloid beta oligomers (AβO) in Alzheimer’s disease (AD) impairs hippocampal long-term potentiation (LTP), leading to memory deficits. Thus, identifying the molecular targets of AβO involved in...

    Authors: Jaedong Lee and Jeehyun Kwag

    Citation: Alzheimer's Research & Therapy 2021 13:165

    Content type: Research

    Published on:

  13. Accumulating evidence suggests that BMI1 confers protective effects against Alzheimer’s disease (AD). However, the mechanism remains elusive. Based on recent pathophysiological evidence, we sought for the first t...

    Authors: Jun Pyo Kim, Bo-Hyun Kim, Paula J. Bice, Sang Won Seo, David A. Bennett, Andrew J. Saykin and Kwangsik Nho

    Citation: Alzheimer's Research & Therapy 2021 13:164

    Content type: Research

    Published on:

  14. This study examined the usefulness of cerebrospinal fluid (CSF) neuron-specific enolase (NSE) levels as a candidate biomarker of neurodegeneration in Alzheimer’s disease (AD), Parkinson’s disease (PD), PD with...

    Authors: Takayuki Katayama, Jun Sawada, Kae Takahashi, Osamu Yahara and Naoyuki Hasebe

    Citation: Alzheimer's Research & Therapy 2021 13:163

    Content type: Research

    Published on:

  15. An increase in lifespan in our society is a double-edged sword that entails a growing number of patients with neurocognitive disorders, Alzheimer’s disease being the most prevalent. Advances in medical imaging...

    Authors: Sergio Grueso and Raquel Viejo-Sobera

    Citation: Alzheimer's Research & Therapy 2021 13:162

    Content type: Research

    Published on:

  16. Alterations in circadian rhythms are present in the presymptomatic stage of Alzheimer’s disease (AD), possibly contributing to its pathogenesis. However, it is unknown whether such alterations are associated w...

    Authors: Adriano D. S. Targa, Iván D. Benítez, Faridé Dakterzada, John Fontenele-Araujo, Olga Minguez, Henrik Zetterberg, Kaj Blennow, Ferran Barbé and Gerard Piñol-Ripoll

    Citation: Alzheimer's Research & Therapy 2021 13:161

    Content type: Research

    Published on:

  17. Neuroleukin (NLK) is a protein with neurotrophic properties and is present in a proportion of senile plaques and amyloid laden vessels. It has been suggested that NLK is part of a neuroprotective response to a...

    Authors: Anna M. De Kort, H. Bea Kuiperij, Daniel Alcolea, Iris Kersten, Alexandra A. M. Versleijen, Steven M. Greenberg, Erik Stoops, Floris H. B. M. Schreuder, Catharina J. M. Klijn, Alberto Lleó, Jurgen A. H. R. Claassen and Marcel M. Verbeek

    Citation: Alzheimer's Research & Therapy 2021 13:160

    Content type: Research

    Published on:

  18. The brainstem locus coeruleus (LC) constitutes the intersection of the initial pathophysiological processes of Alzheimer’s disease (AD) and sleep-wake dysregulation in the preclinical stages of the disease. Ho...

    Authors: Maxime Van Egroo, Roy W. E. van Hooren and Heidi I. L. Jacobs

    Citation: Alzheimer's Research & Therapy 2021 13:159

    Content type: Research

    Published on:

  19. Observational studies have suggested that herpesvirus infection increased the risk of Alzheimer’s disease (AD), but it is unclear whether the association is causal. The aim of the present study is to evaluate ...

    Authors: Shu-Yi Huang, Yu-Xiang Yang, Kevin Kuo, Hong-Qi Li, Xue-Ning Shen, Shi-Dong Chen, Mei Cui, Lan Tan, Qiang Dong and Jin-Tai Yu

    Citation: Alzheimer's Research & Therapy 2021 13:158

    Content type: Research

    Published on:

  20. Preventive interventions for dementia are urgently needed and must be tested in randomised controlled trials (RCTs). Selection (volunteer) bias may limit efficacy, particularly in trials testing multidomain in...

    Authors: Nicola Coley, Delphine Coniasse-Brioude, Valérie Igier, Tristan Fournier, Jean-Pierre Poulain and Sandrine Andrieu

    Citation: Alzheimer's Research & Therapy 2021 13:157

    Content type: Research

    Published on:

  21. For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer’s disease (AD). Machine learni...

    Authors: Louise Bloch and Christoph M. Friedrich

    Citation: Alzheimer's Research & Therapy 2021 13:155

    Content type: Research

    Published on:

  22. Alzheimer’s disease is the most common cause of dementia, and currently, there is no disease-modifying treatment. Favorable functional outcomes and reduction of amyloid levels were observed following transplan...

    Authors: Hee Jin Kim, Kyung Rae Cho, Hyemin Jang, Na Kyung Lee, Young Hee Jung, Jun Pyo Kim, Jung Il Lee, Jong Wook Chang, Seongbeom Park, Sung Tae Kim, Seung Whan Moon, Sang Won Seo, Soo Jin Choi and Duk L. Na

    Citation: Alzheimer's Research & Therapy 2021 13:154

    Content type: Research

    Published on:

  23. Comprehensive testing of cognitive functioning is standard practice in studies of Alzheimer disease (AD). Short-form tests like the Montreal Cognitive Assessment (MoCA) use a “sampling” of measures, administer...

    Authors: Jason Hassenstab, Jessica Nicosia, Megan LaRose, Andrew J. Aschenbrenner, Brian A. Gordon, Tammie L. S. Benzinger, Chengjie Xiong and John C. Morris

    Citation: Alzheimer's Research & Therapy 2021 13:153

    Content type: Research

    Published on:

  24. Although educational interventions are recommended in Alzheimer’s disease (AD), studies assessing the impact of interventions such as “therapeutic patient education” are scarce. Indeed, the intrinsic nature of...

    Authors: Hélène Villars, Christelle Cantet, Eva de Peretti, Amelie Perrin, Maria Soto-martin and Virginie Gardette

    Citation: Alzheimer's Research & Therapy 2021 13:152

    Content type: Research

    Published on:

  25. In Alzheimer’s disease, amyloid- β (A β) peptides aggregate in the lowering CSF amyloid levels - a key pathological hallmark of the disease. However, lowered CSF amyloid levels may also be present in cognitively ...

    Authors: Hákon Valur Dansson, Lena Stempfle, Hildur Egilsdóttir, Alexander Schliep, Erik Portelius, Kaj Blennow, Henrik Zetterberg and Fredrik D. Johansson

    Citation: Alzheimer's Research & Therapy 2021 13:151

    Content type: Research

    Published on:

  26. Aging is associated with declining protective immunity and persistent low-grade inflammatory responses, which significantly contribute to Alzheimer’s disease (AD) pathogenesis. Detecting aging-related cerebral...

    Authors: Lucia Reseco, Mercedes Atienza, Marina Fernandez-Alvarez, Eva Carro and Jose L. Cantero

    Citation: Alzheimer's Research & Therapy 2021 13:150

    Content type: Research

    Published on:

  27. Alzheimer’s disease, cardiovascular disease, and other cardiometabolic disorders may share inflammatory origins. Lipid mediators, including oxylipins, endocannabinoids, bile acids, and steroids, regulate infla...

    Authors: Kamil Borkowski, Theresa L. Pedersen, Nicholas T. Seyfried, James J. Lah, Allan I. Levey, Chadwick M. Hales, Eric B. Dammer, Colette Blach, Gregory Louie, Rima Kaddurah-Daouk and John W. Newman

    Citation: Alzheimer's Research & Therapy 2021 13:149

    Content type: Research

    Published on:

  28. Thoroughly understanding the temporal associations between cognitive and functional dimensions along the dementia process is fundamental to define preventive measures likely to delay the disease’s onset. This ...

    Authors: Sophie Carles, Bachirou O. Taddé, Claudine Berr, Catherine Helmer, Hélène Jacqmin-Gadda, Isabelle Carrière and Cécile Proust-Lima

    Citation: Alzheimer's Research & Therapy 2021 13:148

    Content type: Research

    Published on:

  29. Leukotriene receptor antagonists (LTRAs) alleviate Alzheimer’s disease (AD) pathology and improve cognition in animal models; however, clinical evidence is limited. This study aimed to explore the associations...

    Authors: Lisa Y. Xiong, Michael Ouk, Che-Yuan Wu, Jennifer S. Rabin, Krista L. Lanctôt, Nathan Herrmann, Sandra E. Black, Jodi D. Edwards and Walter Swardfager

    Citation: Alzheimer's Research & Therapy 2021 13:147

    Content type: Research

    Published on:

  30. Identification of reliable, affordable, and easy-to-use strategies for detection of dementia is sorely needed. Digital technologies, such as individual voice recordings, offer an attractive modality to assess ...

    Authors: Chonghua Xue, Cody Karjadi, Ioannis Ch. Paschalidis, Rhoda Au and Vijaya B. Kolachalama

    Citation: Alzheimer's Research & Therapy 2021 13:146

    Content type: Research

    Published on:

  31. To understand the potential for early intervention and prevention measures in Alzheimer’s disease, the association between risk factors and early pathological change needs to be assessed. Hence, the aim of thi...

    Authors: Tobias Möllers, Hannah Stocker, Laura Perna, Andreas Nabers, Dan Rujescu, Annette M. Hartmann, Bernd Holleczek, Ben Schöttker, Klaus Gerwert and Hermann Brenner

    Citation: Alzheimer's Research & Therapy 2021 13:145

    Content type: Research

    Published on:

  32. Epidemiological studies link vascular disease risk factors such as atherosclerosis, hypertension, and diabetes mellitus with Alzheimer’s disease (AD). Whether there are direct links between these conditions to...

    Authors: Min Wang, Junyan Lv, Xiaoshan Huang, Thomas Wisniewski and Wei Zhang

    Citation: Alzheimer's Research & Therapy 2021 13:144

    Content type: Research

    Published on:

  33. While still controversial, it has been demonstrated that vascular defects can precede the onset of other AD hallmarks features, making it an important therapeutic target. Given that the protein transthyretin (...

    Authors: Tiago Gião, Joana Saavedra, José Ricardo Vieira, Marta Teixeira Pinto, Gemma Arsequell and Isabel Cardoso

    Citation: Alzheimer's Research & Therapy 2021 13:143

    Content type: Research

    Published on:

  34. Varoglutamstat (formerly PQ912) is a small molecule that inhibits the activity of the glutaminyl cyclase to reduce the level of pyroglutamate-A-beta (pGluAB42). Recent studies confirm that pGluAB42 is a partic...

    Authors: E. G. B. Vijverberg, T. M. Axelsen, A. R. Bihlet, K. Henriksen, F. Weber, K. Fuchs, J. E. Harrison, K. Kühn-Wache, P. Alexandersen, N. D. Prins and Philip Scheltens

    Citation: Alzheimer's Research & Therapy 2021 13:142

    Content type: Research

    Published on:

  35. To explore whether the combination of white matter hyperintensities (WMHs) and amyloid-beta (Aβ) deposition is associated with worse cognitive performance on cognitive composites (CCs) domain scores in individ...

    Authors: G. Ortega, A. Espinosa, M. Alegret, GC. Monté-Rubio, O. Sotolongo-Grau, A. Sanabria, JP. Tartari, O. Rodríguez-Gómez, M. Marquié, A. Vivas, M. Gómez-Chiari, E. Alarcón-Martín, A. Pérez-Cordón, N. Roberto, I. Hernández, M. Rosende-Roca…

    Citation: Alzheimer's Research & Therapy 2021 13:141

    Content type: Research

    Published on:

  36. Alzheimer’s disease, among other neurodegenerative disorders, spans decades in individuals’ life and exhibits complex progression, symptoms and pathophysiology. Early diagnosis is essential for disease prevent...

    Authors: Valentina Escott-Price and Karl Michael Schmidt

    Citation: Alzheimer's Research & Therapy 2021 13:140

    Content type: Research

    Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2021 13:156

  37. Entrainment of neural oscillations in occipital cortices by external rhythmic visual stimuli has been proposed as a novel therapy for patients with Alzheimer’s disease (AD). Despite this increased interest in ...

    Authors: Alex I. Wiesman, Daniel L. Murman, Pamela E. May, Mikki Schantell, Sara L. Wolfson, Craig M. Johnson and Tony W. Wilson

    Citation: Alzheimer's Research & Therapy 2021 13:139

    Content type: Research

    Published on:

  38. Changes in grey matter covariance networks have been reported in preclinical and clinical stages of Alzheimer’s disease (AD) and have been associated with amyloid-β (Aβ) deposition and cognitive decline. Howev...

    Authors: Wiesje Pelkmans, Rik Ossenkoppele, Ellen Dicks, Olof Strandberg, Frederik Barkhof, Betty M. Tijms, Joana B. Pereira and Oskar Hansson

    Citation: Alzheimer's Research & Therapy 2021 13:138

    Content type: Research

    Published on:

  39. To systematically examine the clinical utility of tau-PET and Braak-staging as prognostic markers of future cognitive decline in older adults with and without cognitive impairment.

    Authors: Davina Biel, Matthias Brendel, Anna Rubinski, Katharina Buerger, Daniel Janowitz, Martin Dichgans and Nicolai Franzmeier

    Citation: Alzheimer's Research & Therapy 2021 13:137

    Content type: Research

    Published on:

  40. Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that has been neuropathologically diagnosed in brain donors exposed to repetitive head impacts, including boxers and American football, soc...

    Authors: Michael L. Alosco, Megan L. Mariani, Charles H. Adler, Laura J. Balcer, Charles Bernick, Rhoda Au, Sarah J. Banks, William B. Barr, Sylvain Bouix, Robert C. Cantu, Michael J. Coleman, David W. Dodick, Lindsay A. Farrer, Yonas E. Geda, Douglas I. Katz, Inga K. Koerte…

    Citation: Alzheimer's Research & Therapy 2021 13:136

    Content type: Research

    Published on:

  41. Perivascular spaces (PVS) have an important role in the elimination of metabolic waste from the brain. It has been hypothesized that the enlargement of PVS (ePVS) could be affected by pathophysiological mechan...

    Authors: Natalia Vilor-Tejedor, Iacopo Ciampa, Grégory Operto, Carles Falcón, Marc Suárez-Calvet, Marta Crous-Bou, Mahnaz Shekari, Eider M. Arenaza-Urquijo, Marta Milà-Alomà, Oriol Grau-Rivera, Carolina Minguillon, Gwendlyn Kollmorgen, Henrik Zetterberg, Kaj Blennow, Roderic Guigo, José Luis Molinuevo…

    Citation: Alzheimer's Research & Therapy 2021 13:135

    Content type: Research

    Published on:

  42. Understanding the changes that occur in the transitional stage between absent and overt amyloid-β (Aβ) pathology within the Alzheimer’s continuum is crucial to develop therapeutic and preventive strategies. The o...

    Authors: Marta Milà-Alomà, Mahnaz Shekari, Gemma Salvadó, Juan Domingo Gispert, Eider M. Arenaza-Urquijo, Grégory Operto, Carles Falcon, Natalia Vilor-Tejedor, Oriol Grau-Rivera, Aleix Sala-Vila, Gonzalo Sánchez-Benavides, José Maria González-de-Echávarri, Carolina Minguillon, Karine Fauria, Aida Niñerola-Baizán, Andrés Perissinotti…

    Citation: Alzheimer's Research & Therapy 2021 13:134

    Content type: Research

    Published on:

  43. We assessed the performance of plasma amyloid oligomerization tendency (OAβ) as a marker for abnormal amyloid status. Additionally, we examined long-term storage effects on plasma OAβ.

    Authors: Rosha Babapour Mofrad, Philip Scheltens, SangYun Kim, Sungmin Kang, Young Chul Youn, Seong Soo A. An, Jori Tomassen, Bart N. M. van Berckel, Pieter Jelle Visser, Wiesje M. van der Flier and Charlotte E. Teunissen

    Citation: Alzheimer's Research & Therapy 2021 13:133

    Content type: Research

    Published on:

  44. In the current study, we aimed to develop an algorithm based on biomarkers obtained through non- or minimally invasive procedures to identify healthy elderly subjects who have an increased risk of abnormal cer...

    Authors: Samantha Prins, Ahnjili Zhuparris, Ellen P. Hart, Robert-Jan Doll and Geert Jan Groeneveld

    Citation: Alzheimer's Research & Therapy 2021 13:132

    Content type: Research

    Published on:

  45. Many patients with Alzheimer’s disease (AD) are physically frail or have substantial functional impairments. There is growing evidence that such patients are at higher risk for medication-induced adverse event...

    Authors: M. Seibert, V. Mühlbauer, J. Holbrook, S. Voigt-Radloff, S. Brefka, D. Dallmeier, M. Denkinger, C. Schönfeldt-Lecuona, S. Klöppel and C. A. F. von Arnim

    Citation: Alzheimer's Research & Therapy 2021 13:131

    Content type: Research

    Published on:

  46. Leukocyte telomere length (LTL) has been shown to predict Alzheimer’s disease (AD), albeit inconsistently. Failing to account for the competing risks between AD, other dementia types, and mortality, can be an ...

    Authors: Fernanda Schäfer Hackenhaar, Maria Josefsson, Annelie Nordin Adolfsson, Mattias Landfors, Karolina Kauppi, Magnus Hultdin, Rolf Adolfsson, Sofie Degerman and Sara Pudas

    Citation: Alzheimer's Research & Therapy 2021 13:130

    Content type: Research

    Published on:

  47. We aimed to systematically describe the burden and distribution of white matter hyperintensities (WMH) and investigate correlations with neuropsychiatric symptoms in pathologically proven Alzheimer’s disease (...

    Authors: Philippe Desmarais, Andrew F. Gao, Krista Lanctôt, Ekaterina Rogaeva, Joel Ramirez, Nathan Herrmann, Donald T. Stuss, Sandra E. Black, Julia Keith and Mario Masellis

    Citation: Alzheimer's Research & Therapy 2021 13:129

    Content type: Research

    Published on:

  48. Cognitive reserve is most commonly measured using socio-behavioural proxy variables. These variables are easy to collect, have a straightforward interpretation, and are widely associated with reduced risk of d...

    Authors: R. Boyle, S. P. Knight, C. De Looze, D. Carey, S. Scarlett, Y. Stern, I. H. Robertson, R. A. Kenny and R. Whelan

    Citation: Alzheimer's Research & Therapy 2021 13:128

    Content type: Research

    Published on:

  49. Although social cognitive dysfunction is a major feature of frontotemporal dementia (FTD), it has been poorly studied in familial forms. A key goal of studies is to detect early cognitive impairment using vali...

    Authors: Hannah D. Franklin, Lucy L. Russell, Georgia Peakman, Caroline V. Greaves, Martina Bocchetta, Jennifer Nicholas, Jackie Poos, Rhian S. Convery, David M. Cash, John van Swieten, Lize Jiskoot, Fermin Moreno, Raquel Sanchez-Valle, Barbara Borroni, Robert Laforce Jr, Mario Masellis…

    Citation: Alzheimer's Research & Therapy 2021 13:127

    Content type: Research

    Published on: